Arrowhead Pharmaceuticals, Inc. (ARWR) vs Axsome Therapeutics, Inc. (AXSM)
A side-by-side comparison of Arrowhead Pharmaceuticals, Inc. and Axsome Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ARWR
Arrowhead Pharmaceuticals, Inc.
$61.35HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
AXSM
Axsome Therapeutics, Inc.
$172.97HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — ARWR vs AXSM
growth of $100 · dividends reinvested · last 10yARWR +755.3% (+23.9%/yr)AXSM +2054.3% (+35.9%/yr)AXSM compounded faster over this window
ARWR AXSM
ARWR vs AXSM: by the numbers
- •AXSM is the larger company ($8.90B vs $8.64B market cap).
- •Both run net losses; AXSM's is the smaller (-24.68% vs -47.79% net margin).
Metrics side by side
Valuation
| Metric | ARWR | AXSM |
|---|---|---|
| P/S ratio | 12.91 | 11.46 |
| P/B ratio | 18.56 | 106.85 |
Profitability
| Metric | ARWR | AXSM |
|---|---|---|
| Gross margin | 100.00% | 93.24% |
| Operating margin | 11.86% | -24.28% |
| Net margin | -47.79% | -24.68% |
| ROE | -68.73% | -230.05% |
| ROIC | -12.12% | -50.82% |
Growth (annualized)
| Metric | ARWR | AXSM |
|---|---|---|
| Revenue CAGR (5Y) | 44.14% | N/A |
| Total return CAGR (5Y) | 0.75% | 41.40% |
Frequently asked
- How have ARWR and AXSM total returns compared?
- Over the past 10 years, ARWR delivered 23.56% and AXSM delivered 35.76% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Arrowhead Pharmaceuticals ROEAxsome Therapeutics ROEArrowhead Pharmaceuticals operating marginAxsome Therapeutics operating marginArrowhead Pharmaceuticals revenue growthAxsome Therapeutics revenue growthArrowhead Pharmaceuticals free cash flowAxsome Therapeutics free cash flow
Arrowhead Pharmaceuticals & Axsome Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.